Use of Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation According to Clinical Profile

References

• Rahman F , KwanGF, BenjaminEJ . Global epidemiology of atrial fibrillation . Nat. Rev. Cardiol.11 ( 11 ), 639 – 654 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , CalderonA, EscobarC, De la FigueraM . Patients with atrial fibrillation in a primary care setting: Val-FAAP study . Rev. Esp. Cardiol.65 ( 1 ), 47 – 53 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lip GY , FauchierL, FreedmanSBet al. Atrial fibrillation . Nat. Rev. Dis. Primers2, 16016 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Pistoia F , SaccoS, TiseoC, DeganD, OrnelloR, CaroleiA . The epidemiology of atrial fibrillation and stroke . Cardiol. Clin.34 ( 2 ), 255 – 268 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Christiansen CB , GerdsTA, OlesenJBet al. Atrial fibrillation and risk of stroke: a nationwide cohort study . Europace doi:10.1093/europace/euv401 ( 2016 ) ( Epub ahead of print ).
   Google Scholar
• Masjuán J , Álvarez-SabínJ, BlancoMet al. Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack . Rev. Neurol.59 ( 1 ), 25 – 36 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Li X , TseVC, Au-DoungLW, WongIC, ChanEW . The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review . Europace doi:10.1093/europace/euw093 ( 2016 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Alvarez-Sabín J , QuintanaM, MasjuanJet al. Economic impact of patients admitted to stroke units in Spain . Eur. J. Health Econ. doi:10.1007/s10198-016-0799-9 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Camm AJ , LipGYH, De CaterinaRet al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association . Eur. Heart J.33 ( 21 ), 2719 – 2747 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC, CalderónA, Rodríguez RocaGC, LlisterriJL, Polo GarcíaJ . Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care . Rev. Esp. Cardiol.67 ( 2 ), 150 – 151 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hart RG , PearceLA, AguilarMI . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation . Ann. Intern. Med.146 ( 12 ), 857 – 867 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Hylek EM , GoAS, ChangYet al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation . N. Engl. J. Med.349 ( 11 ), 1019 – 1026 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC . New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran . Expert Opin. Pharmacother.13 ( 18 ), 2649 – 2661 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ogilvie IM , WelnerSA, CowellW, LipGY . Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation . Am. J. Cardiol.108 ( 1 ), 151 – 161 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kakkar AK , MuellerI, BassandJPet al. GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry . PLoS ONE8 ( 5 ), e63479 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Vanbeselaere V , TruyersC, ElliSet al. Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study . BMC Cardiovasc. Disord.16, 61 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Renoux C , CoulombeJ, SuissaS . Long-term vitamin K antagonists treatment patterns of non-valvular atrial fibrillation (NVAF): a population-based cohort study . BMC Cardiovasc. Disord.16, 84 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Casciano JP , DotiwalaZJ, MartinBC, KwongWJ . The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective . J. Manag. Care Pharm.19 ( 4 ), 302 – 316 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bertomeu-González V , AnguitaM, Moreno-ArribasJet al. FANTASIIA study investigators. Quality of anticoagulation with vitamin K antagonists . Clin. Cardiol.38 ( 6 ), 357 – 364 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC, PrietoLet al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA study . Rev. Esp. Cardiol.68 ( 9 ), 769 – 776 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Pokorney SD , SimonDN, ThomasLet al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry . Am. Heart J.170 ( 1 ), 141 – 148 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Morgan CL , McEwanP, TukiendorfA, RobinsonPA, ClemensA, PlumbJM . Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control . Thromb. Res.124 ( 1 ), 37 – 41 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC . Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications . Expert Rev. Cardiovasc. Ther.11 ( 2 ), 129 – 141 ( 2013 ).
   PubMedGoogle Scholar
• Barrios V , GórrizJL . Atrial fibrillation and chronic kidney disease: focus on rivaroxaban . J. Comp. Eff. Res.4 ( 6 ), 651 – 664 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC . Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice . Future Cardiol.12 ( 4 ), 419 – 433 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC . Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view . Expert Rev. Cardiovasc. Ther.13 ( 7 ), 811 – 824 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Huisman MV , RothmanKJ, PaquetteMet al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF registry Phase II . Am. J. Med.128 ( 12 ), 1306 – 1313 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Connolly SJ , EzekowitzMD, YusufSet al. Dabigatran versus warfarin in patients with atrial fibrillation . N. Engl. J. Med.361 ( 12 ), 1139 – 1151 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Patel MR , MahaffeyKW, GargJet al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation . N. Engl. J. Med.365 ( 10 ), 883 – 891 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Granger CB , AlexanderJH, McMurrayJJet al. Apixaban versus warfarin in patients with atrial fibrillation . N. Engl. J. Med.365 ( 11 ), 981 – 992 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Giugliano RP , RuffCT, BraunwaldEet al. ENGAGE AF-TIMI 48 investigators. Edoxaban versus warfarin in patients with atrial fibrillation . N. Engl. J. Med.369 ( 22 ), 2093 – 2104 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA) . Pradaxa®, “Summary of Product Characteristics” . www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf .
   Google Scholar
• Mani H , Lindhoff-LastE . New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness . Drug Des. Devel. Ther.8, 789 – 798 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gong IY , KimRB . Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban . Can. J. Cardiol.29 ( Suppl. 7 ), S24 – S33 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA) . Xarelto®, “Summary of Product Characteristics” . www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf .
   Google Scholar
• Spencer RJ , AmerenaJV . Rivaroxaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: clinical implications of the ROCKET AF trial and its subanalyses . Am. J. Cardiovasc. Drugs15 ( 6 ), 395 – 401 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA) . Eliquis®, “Summary of Product Characteristics” . www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf .
   Google Scholar
• Song Y , ChangM, SuzukiAet al. Evaluation of crushed tablet for oral administration and the effect of food on apixaban pharmacokinetics in healthy adults . Clin. Ther.38 ( 7 ), 1674.e1 – 1685.e1 ( 2016 ).
   Web of Science ®Google Scholar
• Pujadas-Mestres L , EscolarG, Arellano-RodrigoE, GalánAM . Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation . Drugs Today (Barc.)49 ( 7 ), 425 – 436 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA) . Lixiana®, “Summary of Product Characteristics” . www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf .
   Google Scholar
• Parasrampuria DA , WeilertD, MaaJFet al. Pharmacokinetics and pharmacodynamics of the non-vitamin K antagonist oral anticoagulant edoxaban when administered alone or after switching from rivaroxaban or dabigatran etexilate in healthy subjects . Clin. Drug Investig.36 ( 2 ), 127 – 136 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA , TruittKE . Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa . Clin. Pharmacokinet.55 ( 6 ), 641 – 655 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lip GY . Optimising stroke prevention in elderly patients with atrial fibrillation . J. Thromb. Haemost. doi:10.1111/jth.13480 ( 2016 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Simon TA , PanX, KawabataH, HuangHY, AzoulayL . The association between bleeding and the incidence of warfarin discontinuation in patients with atrial fibrillation . Cardiovasc. Ther.34 ( 2 ), 94 – 99 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Larsen TB , Skj⊘thF, NielsenPB, KjældgaardJN, LipGY . Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study . BMJ353, i3189 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Potpara TS , LipGY . Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk . Prog. Cardiovasc. Dis.58 ( 2 ), 177 – 194 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Diener HC , ConnollySJ, EzekowitzMDet al. RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial . Lancet Neurol.9 ( 12 ), 1157 – 1163 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Hankey GJ , PatelMR, StevensSRet al. ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF . Lancet Neurol.11 ( 4 ), 315 – 322 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Easton JD , LopesRD, BahitMCet al. ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial . Lancet Neurol.11 ( 6 ), 503 – 511 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rost NS , GiuglianoRP, RuffCTet al. ENGAGE AF-TIMI 48 Investigators. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48) . Stroke47 ( 8 ), 2075 – 2082 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• O’Neal WT , SalahuddinT, BroughtonST, SolimanEZ . Atrial fibrillation and cardiovascular outcomes in the elderly . Pacing Clin. Electrophysiol.39 ( 9 ), 907 – 913 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Violi F , SolimanEZ, PignatelliP, PastoriD . Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms . J. Am. Heart Assoc.5 ( 5 ), e003347 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Soliman EZ , SaffordMM, MuntnerPet al. Atrial fibrillation and the risk of myocardial infarction . JAMA Intern. Med.174 ( 1 ), 107 – 114 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Aguilar MI , HartR, PearceLA . Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks . Cochrane Database Syst. Rev.3, CD006186 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Pastori D , PignatelliP, SaliolaMet al. Inadequate anticoagulation by vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation . Int. J. Cardiol.201, 513 – 516 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Connolly SJ , EzekowitzMD, YusufS, ReillyPA, WallentinL . Newly identified events in the RE-LY trial . N. Engl. J. Med.363, 1875 – 1187 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Mahaffey KW , StevensSR, WhiteHDet al. ROCKET AF investigators. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial . Eur. Heart J.35 ( 4 ), 233 – 241 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tsiachris D , TsioufisC, MazzoneP, KatsikiN, StefanadisC . Atrial fibrillation and chronic kidney disease in hypertension: a common and dangerous triad . Curr. Vasc. Pharmacol.13 ( 1 ), 111 – 120 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hart RG , PearceLA, AsingerRW, HerzogCA . Warfarin in atrial fibrillation patients with moderate chronic kidney disease . Clin. J. Am. Soc. Nephrol.6 ( 11 ), 2599 – 2604 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Holden RM , ClaseCM . Use of warfarin in people with low glomerular filtration rate or on dialysis . Semin. Dial.22 ( 5 ), 503 – 511 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ng KP , EdwardsNC, LipGY, TownendJN, FerroCJ . Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation . Am. J. Kidney. Dis.62 ( 3 ), 615 – 632 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hart RG , EikelboomJW, IngramAJ, HerzogCA . Anticoagulants in atrial fibrillation patients with chronic kidney disease . Nat. Rev. Nephrol.8 ( 10 ), 569 – 578 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kooiman J , van ReinN, SpaansBet al. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease . PLoS ONE9 ( 5 ), e94420 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Limdi NA , NolinTD, BoothSLet al. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study . Am. J. Kidney. Dis.65 ( 5 ), 701 – 709 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Brodsky SV , NadasdyT, RovinBHet al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate . Kidney Int.80 ( 2 ), 181 – 189 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Górriz JL , MolinaP, CerverónMJet al. Vascular calcification in patients with nondialysis CKD over 3 years . Clin. J. Am. Soc. Nephrol.10 ( 4 ), 654 – 666 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hijazi Z , HohnloserSH, OldgrenJet al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis . Circulation129 ( 9 ), 961 – 970 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Musso CG , JaureguiJR, Macías NúñezJF . Frailty phenotype and chronic kidney disease: a review of the literature . Int. Urol. Nephrol.47 ( 11 ), 1801 – 1807 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Khan F , HuangH, DattaYH . Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation . J. Thromb. Thrombolysis42 ( 4 ), 573 – 578 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Fox KA , PicciniJP, WojdylaDet al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment . Eur. Heart J.32 ( 19 ), 2387 – 2394 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH , HijaziZ, ThomasLet al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial . Eur. Heart J.33 ( 22 ), 2821 – 2830 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Alexander JH , AnderssonU, LopesRDet al. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial . JAMA Cardiol.1 ( 6 ), 673 – 678 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Bohula EA , GiuglianoRP, RuffCTet al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial . Circulation134 ( 1 ), 24 – 36 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Chan KE , EdelmanER, WengerJB, ThadhaniRI, MadduxFW . Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis . Circulation131 ( 11 ), 972 – 979 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC, EcharriR . Importance of medication adherence from the ONTARGET and TRANSCEND points of view . Fundam. Clin. Pharmacol.23 ( 2 ), 259 – 260 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC . From clinical trials to clinical practice. Experience with rivaroxaban in the anticoagulant treatment of patients with non-valvular atrial fibrillation . Semergen doi:10.1016/j.semerg.2016.01.016 ( 2016 ) ( Epub ahead of print ).
   PubMedGoogle Scholar
• Graham DJ , ReichmanME, WerneckeMet al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation . Circulation131 ( 2 ), 157 – 164 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Russo V , BianchiV, CavallaroCet al. Efficacy and safety of dabigatran in a ‘real-life’ population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry . Eur. Rev. Med. Pharmacol. Sci.19 ( 20 ), 3961 – 3967 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A , Skj⊘thF, LarsenTBet al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study . J. Thromb. Haemost.13 ( 4 ), 495 – 504 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Camm AJ , AmarencoP, HaasSet al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation . Eur. Heart J.37 ( 14 ), 1145 – 1153 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Coleman CI , AntzM, SimardEet al. Real-world evidence on stroke prevention in patients with atrial fibrillation in the United States . J. Interv. Card. Electrophysiol.45, 233 – 233 ( 2016 ).
   PubMedGoogle Scholar
• Blann AD , BanerjeeA, LaneDA, Torp-PedersenC, LipGY . Net clinical benefit of edoxaban versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study . Int. J. Cardiol.201, 693 – 698 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr , ReillyPA, EikelboomJet al. Idarucizumab for dabigatran reversal . N. Engl. J. Med.373 ( 6 ), 511 – 520 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Crowther M , CrowtherMA . Antidotes for novel oral anticoagulants: current status and future potential . Arterioscler. Thromb. Vasc. Biol.35 ( 8 ), 1736 – 1745 ( 2015 ).
   PubMed Web of Science ®Google Scholar